Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04692064 · ClinicalTrials.gov registry record
mCVI Confirmatory Clinical Study: Algorithm Verification
A clinical trial of Algorithm Verification, sponsored by Intelomed.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT04692064: Completed study of Algorithm Verification, sponsored by Intelomed.
NCT04692064 is a study of Algorithm Verification that has completed, run by Intelomed. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04692064, a study of Algorithm Verification, has completed, sponsored by Intelomed.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This single center confirmatory clinical study is to verify the algorithm of mCVI® to accurately capture pulse rate and respiratory rate in 20 healthy subjects in comparison to commercially-available Masimo pulse oximeter devices. This is a non significant risk device.
Primary Outcome
To demonstrate that mCVI® accurately captures pulse rate in comparison to Masimo pulse oximeter devices
Conditions Studied
Interventions
- OTHER There is no intervention
Study Locations (1)
Pennsylvania
- InteloMed, Inc. - Cranberry Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2021-02-21 |
What the finished NCT04692064 record still lists
NCT04692064 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Algorithm Verification appearing as the primary indexed condition, and to 1 intervention - of which There is no intervention is the first listed.
NCT04692064 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04692064 about?
NCT04692064 is a clinical study titled "mCVI Confirmatory Clinical Study: Algorithm Verification". This single center confirmatory clinical study is to verify the algorithm of mCVI® to accurately capture pulse rate and respiratory rate in 20 healthy subjects in comparison to commercially-available Masimo pulse oximeter devices. This is a non significant risk device.
What is the current status of trial NCT04692064?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2021-02-03. Estimated completion is 2021-02-21.
What conditions does trial NCT04692064 study?
This clinical trial studies the following conditions: Algorithm Verification.
What interventions are being tested in trial NCT04692064?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT04692064?
This trial is sponsored by Intelomed, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04692064 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI